- iKang Healthcare Group, Inc. (KANG): PEGY: 0.38iKang Healthcare Group, Inc. ( KANG ) is a Small Cap stock, in the Healthcare sector, in Medical Laboratories industry and based in China.
Analysts rate this stock a strong buy!
iKang Healthcare Group, Inc., incorporated on May 25, 2011, provides
preventive healthcare solutions. The Company’s solutions include a
range of medical examinations services, including disease screening,
dental services and other services in China. The Company operates
through two segments: medical examinations and other medical services,
and dental services. As of March 31, 2015, its network consisted of 58
self-owned medical centers and its self-owned medical center network
covered 15 of the affluent cities in China, such as Beijing, Shanghai,
Guangzhou, Shenzhen, Chongqing, Tianjin, Nanjing, Suzhou, Hangzhou,
Chengdu, Fuzhou, Changchun, Jiangyin, Changzhou and Shenyang, as well
as Hong Kong. Its nationwide network offers a range of medical
examination services and provides solution to its corporate customers.
It also provides its customers with consultation and medical referrals
for additional as-needed diagnosis or treatment.The Pros on this stock include:
The analysts like this stock. The PEGY Ratio is very good (0.38 <= 1) meaning that the growth and yield is larger than the Price/Earnings ratio, an excellent growth value. The five year estimated growth is good (45.00%). The Price to Book Ratio is a good 3.14 (under 5). The EV to EBITDA Ratio good (14.17), less than the average. The Profit Margin is positive. The Operating Margin is positive. The Return on Equity is good. The Return on Assets is good.
The Cons on this stock include:
In the short term chart, the stock is below its 50 Day Moving Average (-6.81 %). In the long term chart, the stock is below its 200 Day Moving Average (-11.06 %) The stock is underpeforming the S&P 500 over the last 52 weeks by -18.56 %.The Price to Cash Ratio 15.76 is higher than average. Company has less cash as a percent of price than average.
There were recent articles about KANG:
- 8:33 am iKang Healthcare Group receives preliminary
- iKang Announces Receipt of Preliminary Non-Binding “Going
- Edited Transcript of KANG earnings conference call or
- iKang Healthcare Group Inc Earnings Call scheduled for 8:00 am
- Q1 2015 iKang Healthcare Group Inc Earnings Release – Time Not
- Syneron Medical Ltd. (ELOS): PEGY: 0.46Syneron Medical Ltd. ( ELOS ) is a Small Cap stock, in the Healthcare sector, in Medical Appliances industry and based in Israel.
Analysts rate this stock a strong buy!
Syneron Medical Ltd., incorporated on July 25, 2000, is engaged in
manufacture, research, development, marketing and sales of advanced
equipment for the aesthetic medical industry and systems for
dermatologists, plastic surgeons and other qualified practitioners. The
Company designs, develops and markets aesthetic medical products based
on its various technologies, including Electro-Optical Synergy (ELOS)
technology, which uses the synergy between electrical energy, including
radiofrequency (RF) energy, and optical energy to provide aesthetic
medical treatments. The Company’s products targets an array of
non-invasive aesthetic medical procedures, including hair removal,
wrinkle reduction, rejuvenation of the skin’s appearance through the
treatment of superficial benign vascular and pigmented lesions, acne
treatment, treatment of leg veins, treatment for the temporary
reduction in the appearance of cellulite and thigh circumference,
ablation and resurfacing of the skin, laser-assisted lipolysis and
topical skin brightening products.The Pros on this stock include:
The analysts like this stock. The PEGY Ratio is very good (0.46 <= 1) meaning that the growth and yield is larger than the Price/Earnings ratio, an excellent growth value. The five year estimated growth is good (35.00%). The Price to Cash Ratio is a good 4.15, meaning company has more cash as a percent of price than other companies. The Price to Book Ratio is a good 1.54 (under 5). The stock is shorted less than average too. The Operating Margin is positive. The Return on Assets is good.
The Cons on this stock include:
In the short term chart, the stock is below its 50 Day Moving Average (-10.71 %). In the long term chart, the stock is below its 200 Day Moving Average (-19.64 %) The stock is underpeforming the S&P 500 over the last 52 weeks by -6.27 %.The EV to EBITDA (25.39) is worse than the average (16.22). Profit Margin is negative (-2.01%). Why buy a stock with a negative profit margin? Even Return on Equity is negative (-2.38%).
There were recent articles about ELOS:
- Should You Get Rid of Syneron Medical (ELOS) Now?
- Edited Transcript of ELOS earnings conference call or
- Q2 2015 Syneron Medical Ltd Earnings Release – Before Market
- Syneron Medical reports 2Q loss
- Syneron Medical Reports Revenue of $73.5 Million for the
- Mallinckrodt Public Limited Company (MNK): PEGY: 0.51Mallinckrodt Public Limited Company ( MNK ) is a Mid Cap stock, in the Healthcare sector, in Drugs – Generic industry and based in Ireland.
Analysts rate this stock a buy.
The Pros on this stock include:
The analysts like this stock. The PEGY Ratio is very good (0.51 <= 1) meaning that the growth and yield is larger than the Price/Earnings ratio, an excellent growth value. The Forward PE is low (10.29). The five year estimated growth is very good (20.29%). The stock has been outperforming the S&P 500 over the last 52 weeks by 1.09%. The Price to Book Ratio is a good 1.86 (under 5). The EV to EBITDA Ratio good (12.25), less than the average. The stock is shorted less than average too. The Operating Margin is positive. The Return on Assets is good.
The Cons on this stock include:
In the short term chart, the stock is below its 50 Day Moving Average (-20.83 %). In the long term chart, the stock is below its 200 Day Moving Average (-28.94 %) The Price to Cash Ratio 43.94 is higher than average. Company has less cash as a percent of price than average. Profit Margin is negative (-2.91%). Why buy a stock with a negative profit margin? Even Return on Equity is negative (-3.81%).
There were recent articles about MNK:
- Mallinckrodt PLC (MNK) Looks Appealing To This Billionaire
- MALLINCKRODT PLC Files SEC form 8-K, Entry into a M
- Strength Seen in Mallinckrodt (MNK): Stock Rises
- Herb’s case for quarterly reports
- HealthCor Management’s Core Health Picks For Q3
- Enzymotec Ltd. (ENZY): PEGY: 0.61Enzymotec Ltd. ( ENZY ) is a Small Cap stock, in the Healthcare sector, in Biotechnology industry and based in Israel.
Analysts rate this stock an okay buy.
Enzymotec Ltd., incorporated on March 8, 1998, is a nutritional
ingredients and medical foods company. The Company’s technologies,
research expertise and clinical validation process enable it to develop
differentiated solutions across a range of products. The Company
operates in two segments: Nutrition segment and VAYA Pharma segment.
Both of the Company’s segments offer a range of products that leverage
its lipid-related offerings. The Company’s clinically-validated
products include bio-functional lipid-based compounds designed to
address dietary needs, medical disorders and common diseases. The
company’s technologies enable it to identify appropriate
lipid-modifying enzymes and then improve the activity of these enzymes,
as well as to enable their use in organic media. These enzymes are then
utilized to restructure lipids found in natural sources, including
krill, fish, vegetable sources and bovine milk.The Pros on this stock include:
The PEGY Ratio is very good (0.58 <= 1) meaning that the growth and yield is larger than the Price/Earnings ratio, an excellent growth value. The five year estimated growth is good (31.85%). The short term stock trend is up (above 50DMA: 22.63%). The long term stock trend is up (above 200DMA: 20.90%). The stock has been outperforming the S&P 500 over the last 52 weeks by 19.84%. The Price to Book Ratio is a good 1.67 (under 5). The stock is shorted less than average too. The Profit Margin is positive. The Operating Margin is positive. The Return on Equity is good. The Return on Assets is good.
The Cons on this stock include:
The Forward PE is high (18.41) but could be worth it if there is enough growth. The Price to Cash Ratio 5.82 is higher than average. Company has less cash as a percent of price than average. The EV to EBITDA (23.73) is worse than the average (16.22).
There were recent articles about ENZY:
- Enzymotec (ENZY) Worth a Look: Stock Up 5.1% in
- Enzymotec Ltd. Granted U.S. Patent for INFAT(R) to Promote
- Will Enzymotec (ENZY) Continue to Surge Higher?
- Enzymotec (ENZY) Catches Eye: Stock Soars 15.2%Zacks (Thu, Aug
- Enzymotec upgraded by Wells Fargo
- Taro Pharmaceutical Industries Ltd. (TARO): PEGY: 0.69Taro Pharmaceutical Industries Ltd. ( TARO ) is a Mid Cap stock, in the Healthcare sector, in Drug Manufacturers – Other industry and based in Israel.
Analysts rate this stock a buy.
Taro Pharmaceutical Industries Ltd. (Taro), incorporated in 1959, is a
science-based pharmaceutical company. The Company develops,
manufactures and markets prescription (Rx) and over-the-counter (OTC)
pharmaceutical products, primarily in the United States, Canada and
Israel. Taro also develops and manufactures active pharmaceutical
ingredients (APIs), primarily for use in its finished dosage form
products. The Company’s primary areas of focus include semi-solids
formulations, such as creams and ointments, and other dosage forms,
such as liquids, capsules and tablets, primarily in the dermatological
and topical, cardiovascular, neuropsychiatric and anti-inflammatory
therapeutic categories.The Pros on this stock include:
The analysts like this stock. The PEGY Ratio is very good (0.68 <= 1) meaning that the growth and yield is larger than the Price/Earnings ratio, an excellent growth value. The Forward PE is low (10.59). The Price to Book Ratio is a good 3.75 (under 5). The EV to EBITDA Ratio good (7.65), less than the average. The stock is shorted less than average too. The Profit Margin is very positive. The Operating Margin is very positive. The Return on Equity is very good. The Return on Assets is very good.
The Cons on this stock include:
In the short term chart, the stock is below its 50 Day Moving Average (-4.24 %). In the long term chart, the stock is below its 200 Day Moving Average (-8.06 %) The stock is underpeforming the S&P 500 over the last 52 weeks by -14.87 %.The Price to Cash Ratio 5.65 is higher than average. Company has less cash as a percent of price than average.
There were recent articles about TARO:
- Taro Pharmaceutical Industries Ltd. Earnings Q1, 2015
- FDA Approves Taro’s Keveyis™ (dichlorphenamide) 50 mg Tablets
- Taro Provides Results for Quarter Ended June 2015Business
- Taro to Announce First Quarter Results on August 6,
- Hikma Pharmaceuticals Plc: Strong price momentum but will it
- Concord Medical Services Holdings Limited (CCM): PEGY: 0.70Concord Medical Services Holdings Limited ( CCM ) is a Micro Cap stock, in the Healthcare sector, in Hospitals industry and based in China.
Analysts rate this stock a sell.
Concord Medical Services Holdings Limited (Concord Medical),
incorporated on November 27, 2007, is a China-based holding company.
The Company, through its subsidiaries, operates a network of
radiotherapy and diagnostic imaging centers in China. As of December
31, 2014, the Company’s network consisted of 139 centers based in 80
hospitals, spanning 56 cities across 25 provinces and administrative
regions in China.The Pros on this stock include:
The PEGY Ratio is very good (0.70 <= 1) meaning that the growth and yield is larger than the Price/Earnings ratio, an excellent growth value. The five year estimated growth is very good (20.00%). The Price to Cash Ratio is a good 1.02, meaning company has more cash as a percent of price than other companies. The Price to Book Ratio is a good 0.25 (under 5). The EV to EBITDA Ratio good (3.13), less than the average. The Profit Margin is very positive. The Operating Margin is very positive. The Return on Equity is good. The Return on Assets is good.
The Cons on this stock include:
The analysts really do not like this stock that much. In the short term chart, the stock is below its 50 Day Moving Average (-10.20 %). In the long term chart, the stock is below its 200 Day Moving Average (-23.92 %) The stock is underpeforming the S&P 500 over the last 52 weeks by -34.47 %.
There were recent articles about CCM:
- Edited Transcript of CCM earnings conference call or
- Concord Medical Services Holdings Ltd Earnings Call scheduled
- Concord Medical Reports Financial Results for the Second
- Q2 2015 Concord Medical Services Holdings Ltd Earnings Release
- Concord Medical Acquires Additional Ownership Interest in MD
- Lumenis Ltd. (LMNS): PEGY: 0.71Lumenis Ltd. ( LMNS ) is a Small Cap stock, in the Healthcare sector, in Medical Appliances industry and based in Israel.
Analysts are neutral on this stock.
Lumenis Ltd., incorporated on December 21, 1991, is a provider of
energy-based, minimally invasive clinical solutions. The Company
operated in three segments: surgical, ophthalmic and aesthetic. It
provides energy-based solutions for both medically necessary and
elective procedures, primarily for the aging population. Its focused
product offerings provide solutions for a range of minimally invasive
procedures. Its solutions include its VersaPulse PowerSuite platform
using high-powered holmium lasers for urologic applications, its M22
multi-energy, multi-application platform for the treatment of various
skin conditions, and its Selecta multi-modality platform for retinal,
secondary cataract and glaucoma therapies. Its products are designed to
help physicians, clinicians and aestheticians to deliver minimally
invasive and effective procedures to their patients in both office and
hospital settings. Its primary target markets for its products are
hospitals, outpatient clinics, ambulatory surgery centers, physicians’
offices, private clinics and aesthetic chains.The Pros on this stock include:
The PEGY Ratio is very good (0.71 <= 1) meaning that the growth and yield is larger than the Price/Earnings ratio, an excellent growth value. The five year estimated growth is very good (24.80%). The short term stock trend is up (above 50DMA: 0.29%). The long term stock trend is up (above 200DMA: 11.83%). The stock has been outperforming the S&P 500 over the last 52 weeks by 66.72%. The Price to Cash Ratio is a good 4.74, meaning company has more cash as a percent of price than other companies. The Price to Book Ratio is a good 4.88 (under 5). The EV to EBITDA Ratio good (15.19), less than the average. The stock is shorted less than average too. The Profit Margin is positive. The Operating Margin is positive. The Return on Equity is good. The Return on Assets is good.
The Cons on this stock include:
There are no Pros in this stock.
There were recent articles about LMNS:
- Prem Watsa Buys 8 Diverse New Holdings in Second
- Lumenis Announces Results of Special Shareholders’
- Photo Release — Lumenis Unveils Valuable Online Resource for
- MULTIMEDIA RELEASE — Lumenis’ LightSheer(R) DESIRE(TM) Laser
- Lumenis Supports the Annual World Head and Neck Cancer
Top 7 PEGY ratio (less than 1.5 is good), non-United States: Healthcare